Mylan Nifedipine Settlement Revised Certification To Paragraph III, FDA Says
Mylan effectively amended its patent certification for its 30 mg extended-release nifedipine from paragraph IV to paragraph III by entering into an agreement with Pfizer to market "authorized generic" variants of Procardia XL and failing to launch its own approved version of the drug, FDA said Feb. 6.
More from Archive
More from Pink Sheet
Newly published insights from a series of European Medicines Agency workshops can guide drug developers in designing development plans that meet the needs of both regulators and health technology assessment bodies.
England’s health technology assessment institute, NICE, is looking to “reimagine” its evaluation process with the help of AI, rather than just using this technology to speed up its existing processes.
Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.